These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1838 related articles for article (PubMed ID: 24909280)

  • 1. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
    Liu Y; Chen X; Luo Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Growth inhibition of combined pathway inhibitors on KRAS mutated non-small cell lung cancer cell line].
    Li ZW; Yang ZL; Feng HL; Bian XC; Liu YY; Liu YQ
    Zhonghua Bing Li Xue Za Zhi; 2013 May; 42(5):330-5. PubMed ID: 24004591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
    Li C; Liu VW; Chan DW; Yao KM; Ngan HY
    Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression of phosphatidylinositol-3 kinase in epithelial ovarian carcinoma].
    Zhang PN; Sun H
    Zhonghua Fu Chan Ke Za Zhi; 2007 Mar; 42(3):196-200. PubMed ID: 17537308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells.
    Nonaka M; Itamochi H; Kawaguchi W; Kudoh A; Sato S; Uegaki K; Naniwa J; Sato S; Shimada M; Oishi T; Terakawa N; Kigawa J; Harada T
    Int J Gynecol Cancer; 2012 Jul; 22(6):922-9. PubMed ID: 22672985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of MTRR gene on apoptosis and autophagy pathways in multiresistant epithelial ovarian cancer].
    Chen J; Wang Q; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2016 Apr; 51(4):285-92. PubMed ID: 27116987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways.
    Kandil E; Tsumagari K; Ma J; Abd Elmageed ZY; Li X; Slakey D; Mondal D; Abdel-Mageed AB
    J Surg Res; 2013 Oct; 184(2):898-906. PubMed ID: 23602735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression and significance of MAPK/ERK in the specimens and cells of epithelial ovarian cancer].
    Jiang XL; Gao JC; Jiang L; Zhang PX; Kang TJ; Sun Q; Qi WJ; Zhang QP; Guan HW; Shi H
    Zhonghua Fu Chan Ke Za Zhi; 2019 Aug; 54(8):541-547. PubMed ID: 31461811
    [No Abstract]   [Full Text] [Related]  

  • 9. [Effects of PI3K/Akt/NF-κB signal pathway on FSH facilitation on cell proliferation and invasion by human epithelial ovarian cancer].
    Xu CL; Lu XL; Yan XN; Wang HL; Chen SQ
    Zhonghua Fu Chan Ke Za Zhi; 2012 Feb; 47(2):134-8. PubMed ID: 22455747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal effect of PI3-K inhibitor LY294002 on P-glycoprotein-mediated multidrug resistance of human leukemia cell line K562/DNR and gastric cancer cell line SGC7901/ADR.
    Zhang Y; Qu XJ; Liu YP; Yang XH; Hou KZ; Teng YE; Zhang JD
    Ai Zheng; 2009 Feb; 28(2):97-9. PubMed ID: 19550116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
    Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway.
    Xu R; Zhang Y; Li A; Ma Y; Cai W; Song L; Xie Y; Zhou S; Cao W; Tang X
    Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 33982772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines.
    Badinloo M; Esmaeili-Mahani S
    Fundam Clin Pharmacol; 2014 Aug; 28(4):414-22. PubMed ID: 23837575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
    Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
    BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
    Park H; Kim Y; Sul JW; Jeong IG; Yi HJ; Ahn JB; Kang JS; Yun J; Hwang JJ; Kim CS
    Prostate; 2015 Nov; 75(15):1747-59. PubMed ID: 26250606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of mitogen-activated protein kinase cascades in inhibition of proliferation in human prostate carcinoma cells by raloxifene: an in vitro experiment].
    Zhang YX; Kong CZ
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):271-5. PubMed ID: 18361842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of PD98059 and LY294002 on subcutaneous xenograft of human endometrial carcinoma in nude mice].
    Guo RX; Zhang RF; Wang XY; Shi HR; Qiao YH
    Zhonghua Fu Chan Ke Za Zhi; 2011 Jun; 46(6):446-52. PubMed ID: 21781587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
    Song H; Zhang J; Ning L; Zhang H; Chen D; Jiao X; Zhang K
    Med Sci Monit; 2018 May; 24():3002-3010. PubMed ID: 29737325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
    Lee HY; Oh SH; Suh YA; Baek JH; Papadimitrakopoulou V; Huang S; Hong WK
    Clin Cancer Res; 2005 Aug; 11(16):6065-74. PubMed ID: 16115952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival.
    Ripple MO; Kalmadi S; Eastman A
    Breast Cancer Res Treat; 2005 Sep; 93(2):177-88. PubMed ID: 16187238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 92.